This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
SUFU Winter Meeting 2013 - Percutaneous tibial nerve stimulation for the treatment of overactive bladder syndrome: Final 36-month results of the STEP study - Poster
March 13, 2013
SUFU Winter Meeting 2013 - Clinical insights into percutaneous tibial nerve stimulation (PTNS) vs. sham therapy for the treatment of overactive bladder syndrome (OAB): Secondary analysis of the SUmiT trial - Poster
March 13, 2013
SUFU Winter Meeting 2013 - Neurostimulation treatment for overactive bladder (OAB): An evaluation of cost effectiveness data - Session Highlights
March 12, 2013
SUFU Winter Meeting 2013 - Overview of AUA/SUFU overactive bladder guidelines - Session Highlights
March 8, 2013
SUFU Winter Meeting 2013 - Overview of AUA/SUFU urodynamics guidelines - Session Highlights
March 7, 2013
GU Cancers Symposium 2013 - Evolving patterns of metastatic disease in castration resistant prostate cancer reported in clinical trials from 1990 to 2011, by William K. Oh, MD, et al. - Session Highlights
February 28, 2013
GU Cancers Symposium 2013 - Poster: Evolving patterns of metastatic disease in castration resistant prostate cancer reported in clinical trials from 1990 to 2011, by William K. Oh, MD, et al.
February 28, 2013
GU Cancers Symposium 2013 - Poster: Bone health among prostate cancer survivors: Long term follow-up from the prostate cancer outcomes study (PCOS), by Alicia Morgans, MD, et al
February 26, 2013
GU Cancers Symposium 2013 - Session Highlights: Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD
February 26, 2013
GU Cancers Symposium 2013 - Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD, et al. - Poster
February 26, 2013
GU Cancers Symposium 2013 - Lower risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists, by Peter Albertsen, MD, et al. - Poster
February 26, 2013
GU Cancers Symposium 2013 - Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials, by E. David Crawford, MD et al. - Poster
February 26, 2013
GU Cancers Symposium 2013 - Galeterone, abiraterone, orteronel and ketoconazole exhibit differential inhibitory effects on CYP17 and steroidogenesis, by Douglas B. Jacoby and Martin Williams - Poster
February 26, 2013
GU Cancers Symposium 2013 - A randomized, phase II, open-label study of sipuleucel-t with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Poster
February 26, 2013
GU Cancers Symposium 2013 - Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis, by Douglas B. Jacoby, et al. - Session Highlights
February 26, 2013
GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer - Session Highlights
February 26, 2013
GU Cancers Symposium 2013 - Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa, by James L. Gulley, et al. - Session Highlights
February 25, 2013
GU Cancers Symposium 2013 - The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study, by Robert van Soest, et al. - Session Highlights
February 25, 2013
GU Cancers Symposium 2013 - Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis, by Jessica Strock, et al. - Session Highlights
February 25, 2013
GU Cancers Symposium 2013 - Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer, by Bertrand Tombal, MD, PhD, et al. - Session Highlights
February 25, 2013
Page 564 of 588
Start
Prev
559
560
561
562
563
564
565
566
567
568
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free